Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- 3 Dreamy Small-Cap Stocks
- Correction or Summer Range Trade?
- Hitting Home Runs & Grand Slams, Not Loud Outs
- Hedge Your Portfolio with the Equity Bear ETF
- Machinery Industry Stock Outlook - May 2013
- Determining Correct Position Size with Options
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 6.67% |
| STEIN MART I | SMRT | 5.38% |
| ALLIANCE FIB | AFOP | 5.21% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
AmerisourceBergen Corporation ( ABC - Analyst Report ) recently announced its decision to supply Express Scripts Holding Company ( ESRX - Analyst Report ) with pharmaceuticals worth $18.5 billion annually. The companies inked a three-year supply deal, which will take effect from October 1, 2012.
We note that Express Scripts has decided not to renew its pharmaceutical distribution agreement with Cardinal Health ( CAH - Analyst Report ) , one of AmerisourceBergen’s competitors, following its expiry on September 30, 2012. The deal contributed $9 billion to Cardinal Health’s annual revenues.
The decision follows Express Scripts’ purchase of Medco Health Solutions in April 2012. The erstwhile Medco Health was the largest customer of AmerisourceBergen, one of the world’s largest pharmaceutical services companies.
Management at AmerisourceBergen stated that the supply deal is expected to account for approximately 23% and 3% of its top and bottom lines, respectively. However, the deal is not expected to impact AmerisourceBergen’s projections for fiscal 2012 (ending September 30) and 2013 disclosed on July 26 while reporting its third quarter fiscal 2012 financial results.
AmerisourceBergen expects to end fiscal 2012 with earnings in the range of $2.80-$2.84 per share on flat-to-modest revenue growth. The company expects operating margin to grow in the high single-digit basis points range. Free cash flow, including capital expenditures of approximately $200 million, is expected in the range of $800- $900 million in fiscal 2012.
The company also provided preliminary expectations for fiscal 2013 while releasing the earnings results. AmerisourceBergen expects its AmerisourceBergen Drug Corporation and AmerisourceBergen Specialty Group units to drive growth in fiscal 2013 aided by generic launches and recent acquisitions. The company anticipates high single digit to low double digit earnings growth in fiscal 2013.
Our Recommendation
We currently have a Neutral recommendation on AmerisourceBergen. The stock carries a Zacks #3 Rank (Hold) in the short run. We have a similar stance on Express Scripts. The Express Scripts contract has removed an overhang for AmerisourceBergen shares.
Read the full reports :
Analyst Report on ABC
Analyst Report on ESRX
Analyst Report on CAH